Last reviewed · How we verify
GLSI-100
GLSI-100 is an autologous dendritic cell vaccine designed to stimulate the immune system to recognize and attack cancer cells expressing specific tumor-associated antigens.
GLSI-100 is an autologous dendritic cell vaccine designed to stimulate the immune system to recognize and attack cancer cells expressing specific tumor-associated antigens. Used for HER2-positive breast cancer (adjuvant setting).
At a glance
| Generic name | GLSI-100 |
|---|---|
| Sponsor | Greenwich LifeSciences, Inc. |
| Drug class | Dendritic cell vaccine |
| Target | HER2 and other tumor-associated antigens |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
The drug is manufactured by isolating a patient's dendritic cells, loading them with tumor-associated peptide antigens (particularly HER2), and reinfusing them to prime T-cell responses against cancer. This personalized immunotherapy approach aims to generate durable anti-tumor immunity by activating both CD4+ and CD8+ T cells against the patient's own malignant cells.
Approved indications
- HER2-positive breast cancer (adjuvant setting)
Common side effects
- Injection site reactions
- Flu-like symptoms
- Fatigue
- Fever
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GLSI-100 CI brief — competitive landscape report
- GLSI-100 updates RSS · CI watch RSS
- Greenwich LifeSciences, Inc. portfolio CI